Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Development of Foxy-5 as a first in class anti-metastatic cancer drug

Reference number
Coordinator Wntresearch AB
Funding from Vinnova SEK 5 000 000
Project duration March 2012 - February 2015
Status Completed

Purpose and goal

The goal of the project was to bring Foxy-5 into humans as an anti-metastatic anti-cancer compound. It was clear from the original project description, that with the funding and the time frame of the Eurostars grant, we could at best reach initiation of a clinical phase 2 study. Due to the results obtained during the preclinical tox testing and the clinical phase 1 study, we decided to introduce a clinical phase 1b study in order to obtain a better basis for selecting the dose of Foxy-5 to be used in the phase 2 study.

Expected results and effects

We have finalized clinical phase 1 and are ready to initiate clinical phase 1b. We expect that we during 2017 can initiate a pivotal randomized clinical phase 2 study which if successful will allow us to apply the Health Authorities for a conditional approval for Foxy-5 use in cancer patients. Moreover, with such data we will be in a very good position to discuss partnerships with big Pharma.

Planned approach and implementation

The clinical results obtained in WP3 were exceptionally positive in that no dose-limiting toxicity was seen with the planned maximum dosing in humans (patients). Thus, WP7 was redesigned to investigate higher dosages and hence also possibly identifying a dose-limiting toxicity at a higher level. In addition, as originally planned for WP7, the analysis of potential biological surrogate markers would possibly give initial signals of efficacy.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 May 2017

Reference number 2012-00116

Page statistics